admedicum GmbH & Co KG

Gemeinsam für eine bessere Allergieversorgung bei Kindern und Jugendlichen: Rückblick auf das 3. FAM-Kid Forum Zum dritten Mal fand das Forum Allergiemanagement im Kindes- und Jugendalter (FAM-Kid) der Initiative Allergiescreening statt – ein Ort des intensiven Austauschs zwischen Fachärztinnen und -ärzten, Vertreterinnen und Vertretern der gesetzlichen Krankenkassen vivida bkk, dem BKK Landesverband Bayern, den Berufsverbänden DGAKI, #GPA und dem BVKJ - Berufsverband der Kinder- und Jugendärzt*innen e.V. sowie der Patientenorganisation Nuss/Anaphylaxie Netzwerk (NAN) e.V.. In diesem Jahr wurde die Veranstaltung von ALK und Thermo Fisher Scientific unterstützt. Mitdiskutiert haben außerdem weitere Vertreter und Vertreterinnen der Initiative Allergiescreening von Sanofi, Stallergenes Greer und Allergopharma GmbH & Co. KG. 💬 Im Mittelpunkt standen die aktuellen Herausforderungen im Allergiemanagement, die Bedeutung frühzeitiger Diagnostik und Therapie sowie der Dialog zwischen allen Akteuren – von Leistungserbringern und politischen Akteuren über Versorger bis hin zu Patient*innen. Besonderes Augenmerk galt der Frage, wie durch gezielte Maßnahmen die frühzeitige Erkennung und Behandlung von Allergien verbessert werden kann. Der praxisorientierte Austausch zeigte einmal mehr, wie wichtig interdisziplinäre Zusammenarbeit ist, um die Versorgungsstrukturen nachhaltig zu stärken und Innovationen im Allergiemanagement voranzutreiben. 🩺💡 Die Initiative Allergiescreening setzt sich mit großem Engagement dafür ein, die Versorgung von Menschen mit Allergien zu verbessern und die Bedeutung frühzeitiger Diagnostik stärker ins Bewusstsein zu rücken. 💚 Ein herzliches Dankeschön an alle Teilnehmenden für die engagierte Diskussion und den wertvollen Beitrag zu einer besseren Versorgung von Allergiepatient*innen! 🤝 Eckard Hamelmann, Prof. Dr. Christian Vogelberg, Manuel Bächle, Detlef Gärtner, Mie Drabinski, Kai Steffen, Katharina Ebner, Simone Weber, Dr. Ghizlane Choukrani, Marion Scholz, Ines Bauer, Klaus Rodens, Claudius Römer, Marcus Heidemann, Christiane Landsberg, Dr. Andreas L.G. Reimann, Daniela Welzel, Ulrike Nowak Mehr Informationen über die Initiative Allergiescreening gibt es unter 📩 [email protected] oder https://lnkd.in/eKEb2mnw #Allergiemanagement #Allergie #Kindergesundheit #Versorgung #Diagnostik #Allergiescreening #Gesundheitswesen #Zusammenarbeit #Patientenversorgung

Exciting News: Global Genes and admedicum Announce Strategic Collaboration! We are thrilled to share that Global Genes (www.globalgenes.org) a leading patient advocacy nonprofit, and admedicum Patient Driven Solutions have launched a strategic partnership to advance patient-driven research in rare diseases. This collaboration brings together Global Genes’ innovative RARE-X platform—empowering patients to own and activate their data for research and drug development—with admedicum’s expertise in patient engagement and multi-stakeholder collaboration. Together, we aim to: - Maximize the impact of RARE-X’s research-grade data for more efficient and meaningful treatment development. - Enable data-driven collaboration between industry, patient organizations, and researchers. - Facilitate access and inclusion, especially for underserved and ultra-rare disease communities. This announcement is especially timely as the World Orphan Drug Congress (WODC) takes place today in Amsterdam. The conversations at WODC make it clear: authentic patient voices, combined with sound genetic and phenotype data, are now essential to foster meaningful therapeutic progress in rare diseases. “Patient driven research is foundational to progress in rare disease. We welcome this partnership with admedicum to scale the impact of the RARE-X platform and accelerate urgently needed rare disease therapy development.” Charlene Son Rigby CEO of Global Genes “By combining Global Genes’ scientific vision, data infrastructure and patient advocacy expertise with admedicum’s operational know-how and deep roots in patient communities and the industry, we are creating a powerful foundation to accelerate solutions that truly matter to patients.” Philipp von Gallwitz & Dr. Andreas L.G. Reimann, Co-Founders and Managing Partners, admedicum We look forward to working with life sciences companies, patient advocacy organizations, and other stakeholders to build a more inclusive, efficient, and patient-driven ecosystem for rare disease research and development. Let’s build a future where patients help lead the way in research and therapeutic innovation! #RareDisease #PatientDriven #Collaboration #WODC #RAREX #GlobalGenes #admedicum Terrapinn Karmen Trzupek Roger Legtenberg ⚛ Robert Pleticha

Read more about the excellent panel discussion at the link

Last week in Barcelona, the myasthenia gravis community— patient organization representatives, researchers and healthcare professionals from around the world—came together at UCB's Rare Disease Connect in Neurology (RDCN). The event was particularly special because it was celebrating the 5th edition of the event! We’re proud to have supported the patient organization track, helping ensure that patient voices were front and center in the discussions. -with Anna Kole, Dr. Helen Sophia Schönborn, Robert Pleticha and EuMGA

  As we approach our 10th anniversary on June 10, 2026, we continue to celebrate the people, projects, and partnerships that have shaped our journey in patient engagement and access. Each month, we’ll countdown and feature one inspiring project that reflects our mission and values. This month’s highlight: Enhancing Decision-Making with Patient Preference Information (PPI) – The Facets of Surgical Treatment for Benign Prostatic Hyperplasia (BPH), a Discrete Choice Experiment with over 300 people living with BPH, sponsored by Boston Scientific: https://lnkd.in/dxbHQNjh Join us on this journey as we look back at some of the most important moments that shaped us. #10YearsOfadmedicum #PatientPreferences #PatientEngagement #PatientExperiences #BPH #SharedDecisionMaking #admedicum Dr. Griebel Claudia Vera Vennedey, Dr. Andreas L.G. Reimann, Philipp von Gallwitz, Roger Legtenberg Christian Hoenig

Today is Mental Health Day and we believe mental health is a key pillar to quality healthcare!

🌍 Excited to share that I’ll be participating in the Clinical Outsourcing Group Europe 2025 conference in Amsterdam, taking place 18–19 November. This event brings together key voices from across the clinical research ecosystem, and I’m looking forward to engaging in inspiring and fruitful discussions with industry partners and patient representatives. These conversations are vital for shaping more inclusive, effective, and patient-centered clinical development strategies. If you’re attending, let’s connect! COGEurope2025 #ClinicalResearch #PatientEngagement #Collaboration #Networking #Amsterdam

❞…’s view is that PED [#PatientExperienceData] should be systematically considered for informing medicines development from the earliest stages (including non-clinical stages) through to post-marketing, since PED can be a relevant contributor to the totality of evidence throughout the medicine lifecycle.❞ News flash! Although we could have written that, it’s actually a redacted quote from the European Medicines Agency’s draft reflection paper on PED, published last week for public consultation. Its purpose is to encourage systematic consideration of PED in medicine development programs and regulatory submissions. Read the full reflection paper here 👉🏽 https://lnkd.in/eJ3tDgph It goes without saying that we couldn’t agree more. Here are some of the reasons we think the EMA paper signals a turning point: 1️⃣ EMA is encouraging the collection and use of PED even before products enter clinical trials, helping to ensure that non-clinical research questions address unmet patient needs. This should serve as a strong signal to companies that postponing these activities until later stages of product development could mean missing critical opportunities to address patient needs and shape more effective medicines from the outset. 2️⃣ PED is defined broadly. EMA emphasizes that data obtained through patient engagement activities should also be considered as part of evidence generation. Such data can add insights into how those that live with a disease experience their condition, symptoms, burden of disease, burden of treatment, quality of life and treatment preferences. 3️⃣ EMA is anticipating a future where rich and complementary data from patient preference studies, programs including patient-reported outcomes, surveys, consultations, focus groups, interviews and stakeholder workshops may all become an integral part of any drug developer’s evidence base. Interested parties have until January 2026 to review the content of EMA’s draft paper and suggest which elements are missing and how the regulator’s position could potentially be improved. admedicum is excited to be part of this initiative in the months ahead. #admedicum #patientexperiences #patientengagement #patientinsights #patientinvolvement #patientpreferences #patientreportedoutcomes Dr. Andreas L.G. Reimann Philipp von Gallwitz Roger Legtenberg ⚛

With less than two weeks to go, I’m very much looking forward to moderating a panel discussion on behalf of Partners4Patients Foundation in Barcelona at SCOPE Europe Summit on October 15, 2025. 🎯 The session, entitled “Beyond Checkboxes: Powering Patient-Relevant Clinical Trials through Meaningful Co-Creation & Authentic Collaboration,” promises to deliver valuable insights and dynamic dialogue. I’m looking forward to engaging conversations with a great panel: Bob Stevens from MPS Society UK, here for those with rare diseases; Toni Mathieson from Niemann-Pick UK (NPUK); Daniel Lewi from Cure & Action for Tay-Sachs (CATS) Foundation; and Estrella Garcia from Almirall. Join us in Barcelona for what promises to be a thought-provoking and impactful event. More info: www.SCOPEsummitEurope.com #SCOPEEurope #ClinicalTrials #PatientEngagement #CoCreation #HealthcareInnovation admedicum

We’re excited to share that our colleague Vera Vennedey is attending the International Academy of Health Preference Research (IAHPR) annual meeting in Enschede from Monday, 29th September to Wednesday, 1st October 2025. Vera is our Scientific Lead for Patient Preference Research, and she’s looking forward to connecting with peers and catching up on the latest developments in the field of patient preferences. Find out more here: https://lnkd.in/dGih38c2 #IAHPR2025 #PatientEngagement #PatientPreferences #admedicum